Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04556617 · ClinicalTrials.gov registry record · Phase 1
PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Phase 1 study, sponsored by Opna Bio.
- Terminated
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT04556617 is a Phase 1 study that was terminated before completion, run by Opna Bio. The registered enrollment target is 19 participants.
The verdict
NCT04556617, a Phase 1 study, was terminated before completion, sponsored by Opna Bio.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions
- DRUG Olaparib
- DRUG Prednisone
- DRUG Abiraterone acetate
- DRUG PLX2853 20 mg
- DRUG PLX2853 40 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2020-09-21 |
| Est. Completion | 2022-05-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04556617
The ClinicalTrials.gov registry entry for NCT04556617 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Opna Bio, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Olaparib is the first listed.
NCT04556617 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04556617 about?
NCT04556617 is a clinical study titled "PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)". The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
What is the current status of trial NCT04556617?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2020-09-21. Estimated completion is 2022-05-24.
What interventions are being tested in trial NCT04556617?
The interventions under investigation include: Olaparib (DRUG), Prednisone (DRUG), Abiraterone acetate (DRUG), PLX2853 20 mg (DRUG), PLX2853 40 mg (DRUG).
Who is sponsoring clinical trial NCT04556617?
This trial is sponsored by Opna Bio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.